Histogenics Corp (NASDAQ:HSGX) gapped down before the market opened on Tuesday . The stock had previously closed at $0.21, but opened at $0.20. Histogenics shares last traded at $0.19, with a volume of 3,417,532 shares traded.

Separately, ValuEngine raised Histogenics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Histogenics currently has an average rating of “Buy” and a consensus target price of $2.44.

The firm has a market cap of $17.76 million, a PE ratio of -0.24 and a beta of 3.27. The stock has a fifty day simple moving average of $0.19.

Histogenics (NASDAQ:HSGX) last issued its quarterly earnings data on Wednesday, May 15th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($0.05). As a group, research analysts anticipate that Histogenics Corp will post -0.03 earnings per share for the current year.

An institutional investor recently raised its position in Histogenics stock. Virtu Financial LLC raised its position in shares of Histogenics Corp (NASDAQ:HSGX) by 505.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 592,976 shares of the biotechnology company’s stock after buying an additional 495,096 shares during the period. Virtu Financial LLC owned about 0.63% of Histogenics worth $69,000 as of its most recent filing with the Securities and Exchange Commission. 11.44% of the stock is currently owned by institutional investors and hedge funds.

Histogenics Company Profile (NASDAQ:HSGX)

Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.

Featured Story: What is a short straddle?

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.